ArticleJournal of global oncology2017
Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.
Article in Journal of global oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- Mechanisms, Management and Prognosis of Paraneoplastic Hypercalcemia in Penile Squamous Cell Carcinoma: A Structured Review.Journal of clinical medicine · 2026Review
- Article
- M1 Macrophage-Engineered Vesicles Have Anti-Cancer Activity in Ovarian Cancer.Cancer nanotechnology · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Review of Bone Metastasis in Gynecologic Malignancies: Evaluation and Treatment.Current treatment options in oncology · 2025Review
- [Severe hypercalcemia in intensive care medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
- Low serum creatinine as well as high serum creatinine is associated with prognosis of patients with cancer in end-of-life.Korean journal of family medicine · 2025Article
- Parathyroid hormone-related protein levels and treatment outcomes in hypercalcemia of malignancy: a retrospective cohort study.JBMR plus · 2025Article
- Prevalence and Associated Factors of Hypercalcemia of Malignancy Among Advanced Cancer Patients Attending Palliative Care Unit of a Tertiary Care Hospital in Bangladesh.Cancer reports (Hoboken, N.J.) · 2025Article
- Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report.Case reports in oncological medicine · 2025Article
- Survival Outcomes in Malignancy-related Hypercalcemia: A Tertiary Care Single-center Experience.Journal of cancer & allied specialties · 2024Article
- Gastrointestinal stromal tumour-induced hypercalcaemia.BMJ case reports · 2023Article
- Article
- Association of Albumin-Corrected Serum Calcium Levels with Colorectal Cancer Survival Outcomes.Journal of clinical medicine · 2022Article
- Hypercalcemia of Malignancy: Time to Pull the Brakes.Indian journal of surgical oncology · 2022Article
- Prognostic Scoring System Development for Malignant Spinal Cord Compression.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Review
- Treatment of malignancy-associated hypercalcemia with cinacalcet: a paradigm shift.Endocrine connections · 2021Review
- Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis.Medical oncology (Northwood, London, England) · 2019Article
- Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1.Ecancermedicalscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose Malignancy-related hypercalcemia (MRH) is associated with a dismal prognosis. The widespread use of bisphosphonates (BPs), availability of more effective drugs in cancer treatment, and improvement in supportive care might have attenuated its impact. Patients and Methods To assess overall survival (OS) of patients with MRH in a contemporary setting, we conducted a retrospective analysis of 306 patients with solid cancer hospitalized for symptomatic hypercalcemia. A multivariable Cox proportional hazards regression model was performed to evaluate possible prognostic factors associated with MRH. Results All patients had serum ionized calcium > 5.5 mg/dL or total Ca > 10.5 mg/dL. Median age was 57 years, and the majority had squamous cell carcinoma (62%) and Eastern Cooperative Oncology Group performance status > 1 (96%). Head and neck was the most frequent primary site (28%). Forty-five percent had no previous chemotherapy (CT), and subsequent CT was administered to 32%. Eighty-three percent received BP with no survival gain. Median OS was 40 (95% CI, 33 to 47) days. Patients with a performance status > 2, altered mental status, C-reactive protein > 30 mg/L, albumin < 2.5 g/dL, or body mass index < 18 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.